NCT07249788 Resmiterom Efficacy & Safety in Patients With MASH
| NCT ID | NCT07249788 |
| Status | Recruiting |
| Phase | Phase 4 |
| Sponsor | Nabiqasim Industries (Pvt) Ltd |
| Condition | MASH - Metabolic Dysfunction-Associated Steatohepatitis |
| Study Type | INTERVENTIONAL |
| Enrollment | 165 participants |
| Start Date | 2025-10-17 |
| Primary Completion | 2026-10-16 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
Phase 4 studies follow an already-approved treatment in real-world conditions to monitor long-term safety and effectiveness.
This trial targets 165 participants in total. It began in 2025-10-17 with a primary completion date of 2026-10-16.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
Phase 4 clinical trial study aims to further evaluate the safety and therapeutic efficacy of Resmetirom in Pakistani patients with fibroscan proven MASH.
Eligibility Criteria
Inclusion Criteria: * • At least one metabolic comorbidity (e.g., T2DM, obesity, dyslipidemia and hypertension) * Clinical diagnosis of MASH using: * LSM ≥ 8.5kpa And/or * FAST score ≥0.67 And/or * FibroScan CAP ≥ 275 dB/m And/or * FIB-4 \> 1.3 Exclusion Criteria: * • History of drug addiction and alcoholism * Cirrhosis or decompensated liver disease * Chronic viral hepatitis HBV, HCV) * MACE including MI, Stroke, PE etc. * Pregnant/lactating women * Concurrent use of other investigational drugs * History of other liver diseases (viral, autoimmune, drug-induced, alcohol) * Previous use of resmetirom in last 6 months * Significant renal impairment (eGFR \<30)
Contact & Investigator
Frequently Asked Questions
Who can join the NCT07249788 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, up to 75 Years, studying MASH - Metabolic Dysfunction-Associated Steatohepatitis. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
What phase is the NCT07249788 trial and what does that mean for participants?
Phase 4 studies are conducted after a treatment has been approved. They monitor long-term safety and real-world effectiveness in a broader patient population.
Is NCT07249788 currently recruiting?
Yes, NCT07249788 is actively recruiting participants. Contact the research team at MDR.hussainabidi@gmail.com for enrollment information.
Where is the NCT07249788 trial being conducted?
This trial is being conducted at Rawalpindi, Pakistan.
Who is sponsoring the NCT07249788 clinical trial?
NCT07249788 is sponsored by Nabiqasim Industries (Pvt) Ltd. The trial plans to enroll 165 participants.